Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Manhattan Pharmaceuticals has established the safety of oleoyl estrone, the company's lead product candidate which has been shown to promote weight loss in a number of preclinical animal studies.
Subscribe to our email newsletter
A series of preclinical studies were carried out by Manhattan Pharmaceuticals to evaluate the pharmacological effects of oleoyl estrone (OE) on the central nervous system (CNS), respiratory systems and cardiovascular system in animals. Results of these studies demonstrate that even at high single-dose exposure, OE showed no clinical effect on blood pressure or ECG. There were no adverse effects on respiratory rates or volumes, and no significant changes in CNS parameters.
Further clinical work undertaken by Manhattan highlights the impact of other compounds such as glucocorticoids on OE’s effect, the impact of OE on the level of key cytokines in white adipose tissue, and the potential added value of a reduced calorie diet in combination with OE.
Oleoyl-estrone is believed to be a signaling molecule that acts on the hypothalamus to communicate satiety. It is hypothesized that, in healthy individuals, levels of naturally occurring OE are related to the size of the body’s fat stores, while in obese individuals circulating OE levels are lower than would be expected for the level of body fat.
Orally administered formulations of OE have demonstrated, in extensive preclinical animal studies, to cause significant weight loss and reduce caloric consumption without the need for dietary modifications. In such studies, OE appears to be safe and effective without side effects or evidence of rebound weight gain after treatment was stopped. Manhattan believes that OE may prove to be a safe and effective treatment for obesity, representing a significant advantage over currently available anti-obesity medications.
“Oleoyl estrone continues to demonstrate impressive results in preclinical studies,” said Doug Abel, CEO of Manhattan. Speaking of the recent studies he said the data: “Further supports OE’s potential to provide a substantial improvement over currently available obesity therapeutics, but also provides valuable data for the ongoing design and implementation of our clinical protocols.”